Who is sponsoring NCT04216394?

NCT04216394 is sponsored by Methodist Health System.

What drugs are being tested in NCT04216394?

Interventions in NCT04216394: Emergency general surgery.

What condition does NCT04216394 study?

NCT04216394 studies Emergency General Surgery.

Is NCT04216394 still recruiting?

NCT04216394 is currently completed. Last updated 27 March 2026.

Last reviewed 2026-03-27 · How we verify

NCT04216394

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Anticoagulation in Emergency General Surgery

Completed Last updated 27 March 2026

What this trial tests

trial testing Emergency general surgery in Emergency General Surgery in 4 participants. Completed in 13 November 2020.

Timeline

31 October 2019

Primary endpoint
13 November 2020

13 November 2020

Quick facts

Lead sponsor	Methodist Health System
Status	Completed
Study type	OBSERVATIONAL
Enrollment	4
Start date	31 October 2019
Primary completion	13 November 2020
Estimated completion	13 November 2020
Sites	1 location across United States

Drugs / interventions tested

Emergency general surgery

Conditions studied

Emergency General Surgery — all drugs for Emergency General Surgery →

Sponsor

Methodist Health System — full company profile →

Who can join

18 and older, any sex, with Emergency General Surgery. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

While DOACs are increasing in use in the EGS patient population, the risk of bleeding and the reversal of these agents to reduce hemorrhage is still evolving. Given the paucity of data regarding the impact of DOACs in this patient population, it becomes empiric to identify bleeding patterns and outcomes in the EGS population taking DOACs. We hypothesize that patients taking a DOAC will have a higher bleeding incidence and need for an unplanned intervention secondary to hemorrhage in EGS patients undergoing an urgent or emergent operation when compared to patients taking warfarin and antiplatelets.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Methodist Health System trials

Trials by the same sponsor.

NCT06698302 — Validation of COMPAT-SF Spanish Translation · recruiting
NCT04090034 — Peptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Neuroendocrine Tumors · recruiting
NCT07486362 — Evaluation of Emergency Medicine Pharmacist Impact on Blood Culture Review Following Emergency Department Discharge · recruiting
NCT06222424 — Emergency Medicine Pharmacist Prescriptive Authority for Resolution of Outpatient Prescription Issues · NA · completed
NCT07492758 — Management of Extremity Injuries Registry · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04216394 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Methodist Health System
Last refreshed: 27 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04216394.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing